BioCorRx (BioCorRx) Change In Working Capital : $0.71 Mil (TTM As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is BioCorRx Change In Working Capital?

BioCorRx's change in working capital for the quarter that ended in Dec. 2023 was $0.08 Mil.

BioCorRx's change in working capital for the fiscal year that ended in Dec. 2023 was $0.71 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

BioCorRx Change In Working Capital Historical Data

The historical data trend for BioCorRx's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCorRx Change In Working Capital Chart

BioCorRx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-0.12

0.38

0.70

0.58

0.71

BioCorRx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															0.15	0.31	0.07	0.25	0.08

BioCorRx Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.71 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

BioCorRx Change In Working Capital Related Terms

Thank you for viewing the detailed overview of BioCorRx's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

BioCorRx (BioCorRx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » BioCorRx Inc (OTCPK:BICX) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

2390 East Orangewood Avenue, Suite 500, Anaheim, CA, USA, 92806

Website

https://www.biocorrx.com

BioCorRx Inc through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders. The BioCorRx Recovery Program is a non-addictive, medication-assisted treatment program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application.

Executives

Louis C. Lucido	director	2390 EAST ORANGEWOOD AVENUE, SUITE 500, ANAHEIM CA 92806
Joseph J Galligan	director, 10 percent owner	333 SOUTH GRAND AVENUE, 18TH FLOOR, LOS ANGELES CA 90071
Harsha Murthy	director	5209 38TH STREET,NW, WASHINGTON DC 20015
Luisa Ingargiola	director	4826 BLUE JAY CIRCLE, PALM HARBOR FL 34683
Thomas Patrick Welch	officer: Vice President of Operations	10453 SARAH ST., TOLUCA LAKE CA 91602
Kent Emry	director, officer: Chief Executive Officer	2390 EAST ORANGEWOOD AVENUE, SUITE 500, ANAHEIM CA 92806
Brady James Granier	director	13024 DELANO STREET, VALLEY GLEN CA 91401
Lourdes Felix	director, officer: Chief Financial Officer	15 CALLE VERANO, RANCHO SANTA MARGARITA CA 92688
Jorge Jr Andrade	director, officer: Chief Executive Officer	PO BOX 5366, SANTA ANA CA 92704
Muller Neil Terrence Mr	director, officer: President	13231 SANDHURST PLACE, SANTA ANA CA 92705